

REMARKS

Claim Amendments

After entry of this amendment, claims 6-10, and 22 are pending.

The amendment filed April 23, 2007, failed to incorporate amendments to Claim 6 made in the amendment filed March 7, 2006. Claim 6 is now amended to reflect the amendments made in the paper filed March 7, 2006, and to address objections made in the Office Action mailed July 17, 2007. Specifically, "glutamic acid" replaces "glutamate", "cyclohexylmethylstatine" replaces "cyclohexylmethyistatine", and the phrase " wherein the phenyl group may optionally have mono or di substitution chosen from the group consisting of Cl, F, Br, methyl and methoxy " has been deleted to conform claim 6 to the claim as amended by the March 7, 2006 amendment. In addition, the period in the term "V, A. E and F" has been replaced with a comma to correct the typographical error introduced into the claim in the amendment filed September 25, 2005.

Applicants respectfully submit that the Examiner's rejection to claim 6 as indefinite under 35 U.S.C. 112, second paragraph, based on the term "wherein the phenyl group may optionally have" is moot given the amendments described above. Therefore claim 6 is now in condition for acceptance.

Claims 8 and 9 were rejected because they were dependent on rejected claim 6. Because claim 6 is now in condition for acceptance based on the amendments described above, claims 8 and 9 are also in condition for acceptance.

Claims 7, 10, and 22 were objected to because they were dependent from rejected claims (claims 6, 9, and 6, respectively). Because claims 6 and 9 are now in condition for acceptance, claims 7, 10 and 22 are also in condition for acceptance.

Sequence Listing

The Sequence Error Report in the Office Action mailed July 17, 2007, alleged that the second substitute sequence listing submitted April 23, 2007 contained formatting errors. Specifically, the residue Xaa in SEQ ID NO:73 represented a molecule which is not a amino

Appl. No. 09/730,329
Amdt. dated August 21, 2007
Reply to Office Action of July 17, 2007

PATENT

acid. This matter is corrected in the third substitute sequence listing enclosed herewith. In addition, SEQ ID NOS: 61, 72, 81, 93, 94, 95, 96, 97, 98, 99, and 100 have been amended to correct similar formatting matters. Because these amendments are limited to formatting issues, the third substitute sequence listing contains no new matter.

Applicants submit the third substitute sequence listing correcting formatting matters in computer readable (CRF) and paper formats. The CRF sequence listing was prepared through the use of the software program "PatentIn" and is identical to that of the sequence listing in paper format enclosed herewith in the Appendix. Because the sequence listing is limited to correcting formatting matters, and does not go beyond the sequences disclosed in the application as originally filed, including those in Application 60/168,854 incorporated by reference, or the Figures from Application 60/168,854, it does not constitute new matter.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422

JOL:adm
61127084 v1

Appl. No. 09/730,329
Amdt. dated August 21, 2007
Reply to Office Action of July 17, 2007

PATENT

APPENDIX: Third Substitute Sequence Listing